Veronique Bianco

Veronique Bianco

Auto-generated profile, based on publicly available information

Veronique Bianco

Núcleo de Estudos e Pesquisas em Atenção ao Uso de Drogas (NEPAD), Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 October 2013 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
SHScott A. Halperin
Scott A. Halperin
YBYaela Baine
Yaela Baine
JDJoseph Domachowske
Joseph Domachowske
NANaresh Aggarwal
Naresh Aggarwal
MSMichael Simon
Michael Simon
JMJacqueline M. Miller
Jacqueline M. Miller
Universal immunization of adolescents against meningococcal disease with a quadrivalent meningococcal ACWY (MenACWY) conjugate vaccine is recommended in a number of countries. In a randomized, controlled, observer-blinded, multicenter trial, 1016 participants, 10–25 years of age, were randomly allocated 1:1:1 to receive a single dose of 1 of 2 lots of an investigational tetanus toxoid‐conjugated MenACWY vaccine (MenACWY‐TT) or a marketed diphtheria toxoid‐conjugated MenACWY vaccine (MenACWY‐DT). The primary outcome was the noninferiority of the vaccine response after MenACWY‐TT (lot A) compared with MenACWY‐DT for all 4 serogroups. Vaccine response was defined as a postvaccination human serum bactericidal antibody (hSBA) titer against each of the serogroups of at least 1:8 in persons initially seronegative (<1:4) or as a 4‐fold increase in titer pre‐ to postvaccination in persons initially seropositive (≥1:4). Adverse events (AEs) after immunization were measured 4 and 31 days postvaccination. The mean age of participants was 16.3 years; 977 (96.6%) completed the study. The noninferiority of MenACWY‐TT (lot A) to the control vaccine in terms of the percentage of participants with hSBA vaccine response was demonstrated for each serogroup. Vaccine response rates ranged from 51.0% to 82.5% for the 4 serogroups after MenACWY‐TT (both lots) compared with 39.0%–76.3% for the 4 serogroups after MenACWY‐DT. Pain was the most common injection‐site reaction reported by 50.8%–55.4% across the 3 groups. Fatigue and headache were the most common systemic solicited AEs, reported by 27.3%–29.2% and 25.5%–26.4%, respectively. Tetanus toxoid‐conjugated MenACWY vaccine was well tolerated and elicited an immune response that was noninferior to that of a marketed MenACWY‐DT (www.clinicaltrials.gov NCT01165242).

14 December 2012 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LØLars Østergaard
Lars Østergaard
MWMarie Van der Wielen
Marie Van der Wielen
VBVeronique Bianco
Veronique Bianco
JMJacqueline M. Miller
Jacqueline M. Miller
Objectives A primary dose of the European Union (EU)-licensed meningococcal A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) was immunogenic and well-tolerated in subjects aged 15–19 years. This study assessed antibody persistence at 3.5 years after vaccination with a MenACWY-TT or a tetravalent ACWY polysaccharide vaccine (MenPS, control). Methods In the original study, participants were randomized to receive a single dose of MenACWY-TT or MenPS. Serum bactericidal activity using rabbit serum as exogenous complement source was evaluated up to 42 months post-vaccination. Results At 42 months post-vaccination with MenACWY-TT (n = 19) or MenPS (n = 17), all subjects in each group had serum bactericidal activity titers ≥1:8 against all serogroups, except for two subjects in the MenPS group against serogroup C. Geometric mean antibody titers were higher than pre-vaccination levels at all post-vaccination time-points in both groups, and were significantly higher in the MenACWY-TT group versus the MenPS group for serogroup W-135 at month 42 (exploratory analysis). Conclusions These results indicate that seroprotection following primary vaccination with MenACWY-TT extends more than 3 years. Ongoing persistence data are required to understand the duration of protection following vaccination and to guide decisions on the need for future booster doses.

10 February 2025 in JMIR Mental Health
Verified
Journal Article
Open access
HAHebatullah Abdulazeem
Hebatullah Abdulazeem
INIsrael Júnior Borges do Nascimento
Israel Júnior Borges do Nascimento
IWIshanka Weerasekara
Ishanka Weerasekara
ASAmin Sharifan
Amin Sharifan
VBVictor Grandi Bianco
Victor Grandi Bianco
DNDavid Novillo-Ortiz
David Novillo-Ortiz
Background: Dementia is a syndrome that compromises neurocognitive functions of the individual and that is affecting 55 million individuals globally, as well as global health care systems, national economic systems, and family members. Objective: This study aimed to determine the status quo of scientific production on use of digital health technologies (DHTs) to support (older) people living with dementia, their families, and care partners. In addition, our study aimed to map the current landscape of global research initiatives on DHTs on the prevention, diagnosis, treatment, and support of people living with dementia and their caregivers. Methods: A bibliometric analysis was performed as part of a systematic review protocol using MEDLINE, Embase, Scopus, Epistemonikos, the Cochrane Database of Systematic Reviews, and Google Scholar for systematic and scoping reviews on DHTs and dementia up to February 21, 2024. Search terms included various forms of dementia and DHTs. Two independent reviewers conducted a 2-stage screening process with disagreements resolved by a third reviewer. Eligible reviews were then subjected to a bibliometric analysis using VOSviewer to evaluate document types, authorship, countries, institutions, journal sources, references, and keywords, creating social network maps to visualize emergent research trends. Results: A total of 704 records met the inclusion criteria for bibliometric analysis. Most reviews were systematic, with a substantial number covering mobile health, telehealth, and computer-based cognitive interventions. Bibliometric analysis revealed that the Journal of Medical Internet Research had the highest number of reviews and citations. Researchers from 66 countries contributed, with the United Kingdom and the United States as the most prolific. Overall, the number of publications covering the intersection of DHTs and dementia has increased steadily over time. However, the diversity of reviews conducted on a single topic has resulted in duplicated scientific efforts. Our assessment of contributions from countries, institutions, and key stakeholders reveals significant trends and knowledge gaps, particularly highlighting the dominance of high-income countries in this research domain. Furthermore, our findings emphasize the critical importance of interdisciplinary, collaborative teams and offer clear directions for future research, especially in underrepresented regions. Conclusions: Our study shows a steady increase in dementia- and DHT-related publications, particularly in areas such as mobile health, virtual reality, artificial intelligence, and sensor-based technologies interventions. This increase underscores the importance of systematic approaches and interdisciplinary collaborations, while identifying knowledge gaps, especially in lower-income regions. It is crucial that researchers worldwide adhere to evidence-based medicine principles to avoid duplication of efforts. This analysis offers a valuable foundation for policy makers and academics, emphasizing the need for an international collaborative task force to address knowledge gaps and advance dementia care globally. Trial Registration: PROSPERO CRD42024511241; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=511241

6 November 2025 in JMIR Mental Health
Verified
Journal Article
Open access
INIsrael Júnior Borges do Nascimento
Israel Júnior Borges do Nascimento
HAHebatullah Abdulazeem
Hebatullah Abdulazeem
IWIshanka Weerasekara
Ishanka Weerasekara
ASAmin Sharifan
Amin Sharifan
VBVictor Grandi Bianco
Victor Grandi Bianco
DNDavid Novillo-Ortiz
David Novillo-Ortiz
Background: Population aging has intensified the global burden of dementia, creating significant challenges for patients, caregivers, and health care systems. While traditional in-person dementia care faces barriers, digital health technologies offer promising solutions to enhance accessibility, efficiency, and patient-centered care. However, evidence on applicability, safety, and effectiveness in dementia care remains fragmented, underscoring systematic evaluation. Objective: This study aims to assess the effectiveness, applicability, safety, and cost-efficiency of telemedicine technologies in dementia care, providing a comprehensive summary of evidence spanning clinical, psychological, socioeconomic, and operational impacts for persons living with dementia and their caregivers and assess alignment with the World Health Organization (WHO) Age-friendly Cities and Communities’ Framework and Dementia Inclusive Society Framework. Methods: An overview of systematic and scoping reviews was conducted following a search in 5 databases (MEDLINE, Embase, Scopus, Epistemonikos, and Cochrane Database of Systematic Reviews), with a gray literature search on February 20, 2024. Eligible studies reported predefined outcomes related to telemedicine interventions for integrated dementia care, including effects on mental health, quality of life, physical activity, hospitalization, financial costs, safety, social isolation, and motor function. Screening and data extraction were performed by 10 reviewers. The findings were synthesized using the Thematic Analysis in Meta-Evidence (TAME) methodology, combining thematic and lexical analyses with single-proportion meta-analysis for comprehensive qualitative-quantitative synthesis. The methodological quality was assessed using the AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews), with GRADE-CERQual (Confidence in the Evidence from Reviews of Qualitative Research) for outcomes’ confidence in evidence. Results: Ninety-one reviews provided evidence on the impact of telemedicine in dementia care. The most frequently reported outcomes were the effects of remote interventions on psychiatric and psychological well-being, particularly depression and anxiety (relative frequency of occurrence [RFO]=65%, 95% CI 54-75, moderate certainty of evidence). Fifty-seven studies highlighted the positive impact of telemedicine and telehealth on satisfaction and quality of life for persons living with dementia, caregivers, and health care providers (RFO=63%, 95% CI 52-73, moderate certainty of evidence). Remote technology-related interventions for reducing falls and managing behavioral symptoms were also frequently reported (RFO=33% 95% CI 23-44], moderate certainty of evidence). These interventions showed effectiveness in alleviating social isolation and loneliness (RFO=31%, 95% CI 22-41, moderate certainty of evidence). The methodological quality of the included reviews varied significantly, with the majority rated as low or critically low quality. Conclusions: Telemedicine and telehealth have been demonstrated to be effective and valuable tools in dementia care, offering significant benefits across psychological well-being, quality of life, and social impacts for persons living with dementia and their caregivers. This supports the adoption and implementation of telemedicine in dementia care, aligning with the strategies outlined in the United Nations Decade of Healthy Ageing (2021‐2030).